AKKARAJU SRINIVAS 4
4 · Mineralys Therapeutics, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Mineralys (MLYS) 10% Owner Akkaraju Srinivas Receives Award
What Happened
Akkaraju Srinivas, reported as a 10% owner of Mineralys Therapeutics (MLYS), was granted equity awards on February 19, 2026: 6,200 restricted stock units (RSUs) recorded as an acquisition and 8,300 RSUs recorded as a derivative acquisition — 14,500 units in total. Both grants were issued for no cash consideration (price $0.00), so the reported value at grant is $0. These are awards/compensation, not open-market purchases or sales.
Key Details
- Transaction date(s) and price(s): Feb 19, 2026; 6,200 RSUs @ $0.00 (acquired) and 8,300 RSUs @ $0.00 (derivative).
- Total units granted: 14,500 RSUs; reported grant value $0 at issuance.
- Vesting (F1): These RSUs are contingent rights to receive one share per RSU and vest in one annual installment following the grant date.
- Derivative explanation: The 8,300 units are reported as derivative awards (contingent on vesting).
- Beneficial ownership note (F2): The filing discloses related holdings — 588,235 shares held by Samsara Opportunity Fund, L.P. and 5,282,783 shares held by Samsara BioCapital L.P.; Dr. Akkaraju has voting and investment power over those fund-held shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
- Other footnote (F3): The filing also references a separate stock option vesting schedule (12 monthly installments), which appears unrelated to these RSU grants.
- Filing timeliness: Reported period 2026-02-19 and filed 2026-02-20 (filed next day — timely).
Context
RSU grants are compensation that convert to shares only upon vesting and can be forfeited if vesting conditions aren’t met; they do not represent an immediate open-market purchase or sale. As a reported 10% owner operating through investment vehicles, these awards reflect equity allocation and compensation arrangements rather than a direct personal open-market investment signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-19+6,200→ 6,200 total - Award
Stock Option
[F3]2026-02-19+8,300→ 8,300 totalExercise: $28.06Exp: 2036-02-19→ Common Stock (8,300 underlying)
- 5,871,018(indirect: See footnote)
Common Stock
[F2]
Footnotes (3)
- [F1]Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
- [F2]Of this amount, 588,235 shares are directly held by Samsara Opportunity Fund, L.P. (Samsara Opp LP). Samsara Opportunity Fund GP, LLC (Samsara Opp GP) is the general partner of Samsara Opp LP and may be deemed to beneficially own the securities held by Samsara Opp LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara Opp LP and, accordingly, may be deemed to beneficially own the shares held by Samsara Opp LP. Also, of this amount, 5,282,783 shares are directly held by Samsara BioCapital L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
- [F3]The stock option vests in 12 substantially equal monthly installments following the date of grant.